Dogwood Therapeutics' Halneuron shows promising results in Phase 2b trial for chemotherapy neuropathic pain; Q3 2026 expected for full trial results.
Patients undergoing treatment with Halneuron® showed significant improvement in pain compared to those taking a placebo. The company anticipates releasing the top-line results of the study in the third quarter of 2026.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments